R R

What Is Reyvow?

Reyvow is a prescription medication containing lasmiditan, a selective serotonin 5-HT1F receptor agonist used for the acute treatment of migraine with or without aura in adults. It belongs to a medication class known as ditans and is available as oral tablets. Reyvow treats an existing migraine attack rather than preventing future migraines. Unlike triptans, it does not rely on blood vessel constriction as its primary mechanism. Reyvow is classified as a Schedule V controlled substance in the United States. It can significantly impair driving, so patients must avoid driving or operating machinery for at least eight hours after every dose.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Reyvow?

Reyvow is a prescription medication containing lasmiditan, a selective serotonin 5-HT1F receptor agonist used for the acute treatment of migraine with or without aura in adults. It belongs to a medication class known as ditans and is available as oral tablets. Reyvow treats an existing migraine attack rather than preventing future migraines. Unlike triptans, it does not rely on blood vessel constriction as its primary mechanism. Reyvow is classified as a Schedule V controlled substance in the United States. It can significantly impair driving, so patients must avoid driving or operating machinery for at least eight hours after every dose.

read more about reyvow ...

Copy this HTML:

Copy HTML Copied!

How Does Reyvow Work?

Reyvow activates serotonin 5-HT1F receptors involved in migraine-related nerve signaling. Its action is believed to reduce activity in pathways associated with transmission of migraine pain, although the complete therapeutic mechanism is not fully established. Lasmiditan differs from triptan medications because it does not produce clinically significant vasoconstriction through serotonin 5-HT1B receptors. Its effects on the central nervous system contribute to dizziness, sedation, and impaired coordination. Reyvow can relieve an acute migraine but does not correct the underlying tendency to experience recurring attacks. Patients who require migraine prevention may need a separate treatment plan.

What Type of Migraine Does Reyvow Treat?

Reyvow is approved for acute treatment of migraine attacks with or without aura in adults. Migraine can involve moderate to severe headache, sensitivity to light or sound, nausea, and neurological symptoms such as visual aura. Reyvow is taken when an attack occurs and is not intended as daily preventive treatment. It is not approved for children or for every type of headache. A clinician considers migraine history, other medications, driving requirements, and the risk of sedation before prescribing it. People unable to avoid driving or operating machinery for at least eight hours after administration should not take Reyvow.

How Should Reyvow Be Taken?

Reyvow is taken orally as a single dose of 50 mg, 100 mg, or 200 mg when a migraine attack occurs. No more than one dose should be taken within 24 hours. A second dose has not been shown to provide benefit for the same migraine attack. Tablets may be taken with or without food and should be swallowed whole without crushing, splitting, or chewing. Patients must not drive, operate machinery, or perform hazardous activities requiring full alertness for at least eight hours after taking Reyvow, even if they feel unaffected. The safety of treating an average of more than four migraine attacks in 30 days has not been established.

What Are the Side Effects and Warnings of Reyvow?

Common adverse effects include dizziness, sleepiness, fatigue, tingling sensations, and nausea. Reyvow can cause substantial driving impairment that patients may be unable to recognize themselves. Combining it with alcohol or other sedating medications can increase central nervous system depression. Serotonin syndrome may occur, particularly with other serotonergic medications, and can cause agitation, fever, muscle rigidity, and changes in heart rate. Frequent use of acute migraine medications may also contribute to medication-overuse headache. Reyvow has abuse potential and is classified as a Schedule V controlled substance. Severe confusion, abnormal movements, or symptoms of serotonin syndrome require urgent medical assessment.

Common Questions About Reyvow

Is Reyvow the same as lasmiditan?

Yes. Reyvow is the brand name for lasmiditan, a serotonin 5-HT1F receptor agonist used for acute migraine treatment.

Can Reyvow prevent migraines?

No. Reyvow is approved for treating migraine attacks that have already started, not for preventing future attacks.

How long should patients avoid driving after Reyvow?

Patients must avoid driving and operating machinery for at least eight hours after every dose, even if they feel alert.

Is Reyvow a controlled substance?

Yes. Reyvow contains lasmiditan, which is classified as a Schedule V controlled substance in the United States.

References

DailyMed - REYVOW (lasmiditan) tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aea3358c-ff41-4490-9e6d-c7bf7b3de13f. Date Accessed November 3, 2026.

Lasmiditan. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK572430/. Date Accessed November 3, 2026.

Lasmiditan. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620015.html. Date Accessed November 3, 2026.

Lasmiditan. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lasmiditan. Date Accessed November 3, 2026.

REYVOW Medication Guide. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aea3358c-ff41-4490-9e6d-c7bf7b3de13f. Date Accessed November 3, 2026.